Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors

Stock Information for Portage Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Portage Biotech Inc.

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update
Portage Biotech Reports Business and Strategic Update
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update
Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting
Portage Biotech Announces $6.0 Million Registered Direct Offering
Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.